Literature DB >> 18783338

Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.

Hellinida Thomadaki1, Andreas Scorilas.   

Abstract

We assessed changes in the apoptosis-related genes BCL2, BAX, BCL2L12, FAS and CASPASE-3 in OVCAR-3 human ovarian cancer cells and BT-20 human breast cancer cells to provide an insight into the molecular mechanisms involved in the response of these cells to treatment with anticancer drugs and to assess their value as potential biomarkers of chemotherapy response in breast and ovarian cancer. Cells were treated with different chemotherapeutic drugs (cisplatin, carboplatin, doxorubicin, etoposide and taxol) and assessed for changes in the expression of apoptosis-related genes at the mRNA level. Total RNA was extracted, reverse-transcribed into cDNA and amplified by PCR using gene-specific primers. GAPDH was used as a housekeeping gene. Cytotoxicity was assessed by MTT assay. Both cancer cell lines responded differentially at the molecular level to the drug treatments. OVCAR-3 cells showed more pronounced sensitivity and changes compared to BT-20 cells at the mRNA level for different apoptosis-related genes, leading to cell and cancer type dependence in conjunction with drug dependence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783338     DOI: 10.1515/BC.2008.161

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  9 in total

1.  Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.

Authors:  Ju-Hwa Kim; Minji Chae; Won Ki Kim; You-Jin Kim; Han Sung Kang; Hyung Sik Kim; Sungpil Yoon
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells.

Authors:  Dimitra Florou; Christos Patsis; Alexandros Ardavanis; Andreas Scorilas
Journal:  Cancer Biol Ther       Date:  2013-05-10       Impact factor: 4.742

3.  Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.

Authors:  Dimitrios Korbakis; Andreas Scorilas
Journal:  Tumour Biol       Date:  2012-01-12

4.  BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma.

Authors:  Ali Fendri; Christos K Kontos; Abdelmajid Khabir; Raja Mokdad-Gargouri; Andreas Scorilas
Journal:  Mol Med       Date:  2010-12-08       Impact factor: 6.354

5.  Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.

Authors:  Fernanda Musa; Amandine Alard; Gizelka David-West; John P Curtin; Stephanie V Blank; Robert J Schneider
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

6.  Cisplatin downregulates BCL2L12, a novel apoptosis-related gene, in glioblastoma cells.

Authors:  Mahdieh Sadat Taghavi; Azim Akbarzadeh; Reza Mahdian; Kayhan Azadmanesh; Gholamreza Javadi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-05-25       Impact factor: 2.416

7.  The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents.

Authors:  Dimitra Florou; Konstantinos Mavridis; Andreas Scorilas
Journal:  Tumour Biol       Date:  2012-09-05

8.  Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.

Authors:  Georgia Papachristopoulou; Maroulio Talieri; Andreas Scorilas
Journal:  Tumour Biol       Date:  2012-10-20

9.  Cucurbita ficifolia Fruit Extract Induces Tp53/Caspase-Mediated Apoptosis in MCF-7 Breast Cancer Cells.

Authors:  Ghedeir M Alshammari; Aristatile Balakrishnan; Ali A Alshatwi; Abdulrahman Al-Khalifa
Journal:  Biomed Res Int       Date:  2020-06-25       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.